|
Hemato-oncology
Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system
Sang Eun Yoon, Won Seog Kim, Seok Jin Kim
Korean J Intern Med. 2020;35(4):946-956. Published online November 25, 2019
Background/Aims: There are limited data about the influence of the central nervous system (CNS) involvement on the prognosis for patients with the Asian variant of intravascular large B-cell lymphoma (IVLBCL).
Methods: We analyzed 46 patients who were diagnosed with IVLBCL between 2001 and 2018. Al..
|
|
|
Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
Koung Jin Suh, Ki Hwan Kim, Ryul Kim, Ja Min Byun, Miso Kim, Jin Hyun Park, Bhumsuk Keam, Tae Min Kim, Jin-Soo Kim, In Sil Choi, Dae Seog Heo
Korean J Intern Med. 2019;34(4):894-901. Published online February 23, 2018
Background/Aims: The role of [18F]-f luorodeoxyglucose positron emission tomography-computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) in first remission is unclear.
Methods: Medical costs within the first 3 years of treatment completion and clinical outcomes of 118..
|
|
|
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Korean J Intern Med. 2019;34(4):885-893. Published online November 20, 2017
Background/Aims: This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy.
Methods..
|
|
|
Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy
Seul Lee, Dong Hyun Kim, Sung Yong Oh, So Yeon Kim, Myeong Seok Koh, Ji Hyun Lee, Suee Lee, Sung-Hyun Kim, Jong-Young Kwak, Min Gyoung Pak, Mi Ha Ju, Hyo-Jin Kim, Jin Sook Jeong
Korean J Intern Med. 2017;32(2):335-344. Published online March 11, 2016
Background/Aims: CD11c is a dendritic cell marker in humans, which potentially induces a cytotoxic effect on lymphoma cells. Forkhead boxP3 (FOXP3) is a regulator of T lymphocyte in the microenvironment of the lymphoma. The principal objective of this study was to determine whether the tumors’ mic..
|
|
|
Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review
Yun Hwa Jung, In Sook Woo, Chi Wha Han
Korean J Intern Med. 2015;30(5):684-693. Published online August 27, 2015
Background/Aims: Among diffuse large B cell lymphoma (DLBCL) patients, determining the appropriate dose and chemotherapy schedule to balance toxicity and efficacy is harder in elderly than in younger patients. Moreover, there are no currently available clinical factors that consistently identify pat..
|
|
|
Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients
Jae-Ho Yoon, Jong-Wook Kim, Young-Woo Jeon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Seok-Goo Cho
Korean J Intern Med. 2015;30(3):362-371. Published online April 29, 2015
Background/Aims: Several studies have demonstrated the effect of autologous hematopoietic stem cell transplantation (auto-HSCT) as a salvage treatment for patients with relapsed diffuse large B-cell lymphoma (DLBCL). However, the role of auto-HSCT as a frontline treatment has not been fully investig..
|
|
|
Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
Changhoon Yoo, Shin Kim, Byeong Seok Sohn, Jeong-Eun Kim, Dok Hyun Yoon, Jooryung Huh, Dae Ho Lee, Sang-We Kim, Jung-Shin Lee, Cheolwon Suh
Korean J Intern Med. 2010;25(3):301-308. Published online August 31, 2010
Background/AimsRituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI). We evaluat..
|
|
|
